Welcome to our dedicated page for Hologic SEC filings (Ticker: HOLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hologic, Inc. filings document the company’s transition from a Nasdaq-listed public issuer to a private company after its completed acquisition by funds managed by Blackstone and TPG. The record includes Form 25 notice for removal of Hologic common stock from Nasdaq listing and Form 15 certification to terminate registration or suspend Exchange Act reporting duties for its common stock.
Related 8-K disclosures cover material events, merger-related agreements and shareholder voting matters, capital-structure disclosures, governance and compensation arrangements, operating results, and clinical or regulatory developments tied to Hologic’s women’s health medical-technology business.
Hologic Inc. executive Mark W. Horvath has exited all company equity as part of a completed cash merger. On April 7, 2026, he disposed of 23,026 shares of Hologic common stock back to the company, along with multiple non-qualified stock options and performance stock units.
The option awards covering a total of 20,596 underlying shares at exercise prices ranging from $65.24 to $79.39 were canceled and converted into the merger consideration. In addition, 7,762 performance stock units were certified by the board’s compensation committee and then canceled for the same merger consideration.
Under the merger, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right that can pay up to $3.00 in cash. Following these transactions, Horvath no longer beneficially owns any Hologic common stock, and the dispositions reflect payouts under the merger agreement rather than open-market trading.
Hologic Inc. senior vice president of human resources Diana De Walt disposed of 7,603 shares of common stock in connection with the company’s merger into Hopper Parent Inc. Each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right (CVR) worth up to $3.00 in cash, if payable. As a result of this merger-related conversion, De Walt no longer beneficially owns any Hologic common shares.
Hologic, Inc. director Amy McBride disposed of her equity awards and shares in connection with the company’s merger. On April 7, 2026, multiple non-qualified stock option grants, each covering between 1,500 and 7,551 shares of common stock at exercise prices from $38.44 to $78.49, were reported as dispositions to the issuer, leaving 0 derivative securities outstanding for each grant.
On the same date, 25,784 shares of Hologic common stock were also reported as a disposition to the issuer. Under the merger, each share of common stock was converted into the right to receive $76.00 in cash plus one contingent value right for up to an additional $3.00 in cash per share. The filing notes that McBride’s time-vesting restricted stock units were converted into the same merger consideration and that she no longer beneficially owns any Hologic common stock.
Hologic, Inc. director Stacey D. Stewart reported returning stock awards to the company in connection with a completed merger. On April 7, 2026, he disposed of 15,049 non‑qualified stock options covering Hologic common stock at exercise prices between $64.36 and $78.49, plus 8,358 shares of common stock, all as issuer dispositions.
Footnotes explain that under an Agreement and Plan of Merger, each Hologic common share was converted into the right to receive $76.00 in cash and one contingent value right of up to $3.00 in cash. Time‑vesting restricted stock units were similarly converted, and Stewart no longer beneficially owns any Hologic common stock.
Hologic, Inc. director Christiana Stamoulis reported the cash-out of her equity in connection with a merger. All reported holdings, including 50,526 shares of common stock and several non-qualified stock option grants, were disposed of to the issuer, leaving her with no remaining Hologic equity.
Under the merger, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right that may pay up to an additional $3.00 in cash per share.
Hologic, Inc. director Nanaz Mohtashami reported dispositions tied to the company’s merger with Hopper Parent Inc. At the merger’s effective time, each Hologic common share converted into $76.00 in cash plus one contingent value right worth up to $3.00 in cash when and if payable.
On that date, Mohtashami disposed of non-qualified stock options covering 2,141, 4,536, and 5,535 shares at exercise prices of $71.45, $76.32, and $64.36, respectively, along with 7,371 common shares, all back to the issuer. The filing notes that, as a result of the merger, Mohtashami no longer beneficially owns any Hologic common stock.
Hologic Inc director Wayde D. McMillan reported the disposition of his company equity in connection with the closing of a merger. He surrendered 5,171 non-qualified stock options with a $61.27 exercise price and 4,932 shares of common stock back to the issuer.
Under the merger agreement with Hopper Parent Inc., each Hologic common share was converted into the right to receive $76.00 in cash plus one contingent value right that may pay up to an additional $3.00 in cash. McMillan’s time-vesting restricted stock units were similarly converted, and as a result he no longer beneficially owns any Hologic common stock.
Hologic Inc. director Martin D. Madaus reported dispositions of all remaining equity interests in connection with the company’s merger. On April 7, 2026, he surrendered 1,016 and 5,535 non-qualified stock options with exercise prices of $75.79 and $64.36 per share, respectively, plus 5,396 shares of common stock held directly and 5,445 shares held through a revocable trust, all as dispositions to the issuer.
Under the Merger Agreement, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right of up to $3.00 in cash per share. As a result of the merger, Madaus no longer beneficially owns any Hologic common stock, directly or indirectly.
Hologic CEO Stephen MacMillan reports the cancellation of his Hologic equity holdings in connection with the company’s merger. At the merger’s effective time, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right for up to an additional $3.00 in cash.
His time-vesting restricted stock units and performance stock units were converted into cash-based rights to the same merger consideration structure. Following these conversions and dispositions, the filing states that MacMillan no longer beneficially owns, directly or indirectly, any shares of Hologic common stock.
Hologic director Ludwig Hantson reported the disposition of his equity awards in connection with the company’s merger. On April 7, 2026, multiple non-qualified stock options covering thousands of shares of Hologic common stock and 16,146 common shares were disposed of to the issuer.
Under the merger agreement, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right, which may pay up to $3.00 in cash. Time-vesting restricted stock units held by Hantson were similarly converted into this merger consideration, and he no longer beneficially owns any Hologic common shares.